Boston Scientific (BSX) is back in focus after its 29 July 2026 earnings release, which included updated 2026 sales guidance and fresh detail on restructuring, product pressures and a recent device recall.

Boston Scientific’s recent earnings beat, updated guidance and the recall news have come against a backdrop of mixed momentum, with the 1 month share price return of 8.52% contrasting with a year to date share price decline of 50.66% and a 1 year total shareholder return that is down 55.67%.

If you are weighing Boston Scientific’s setup after this guidance reset and recall, it can be useful to see what else is moving in the sector through the 41 healthcare AI stocks

Boston Scientific still looks like a high quality medical device business, even after a recall, lower guidance and a sharp share price reset. The real issue now is whether that strength already sits fully in the price.

Most Popular Narrative: 35.3% Undervalued

Against Boston Scientific’s last close of $46.73, the most followed narrative points to a fair value of $72.25, which implies a wide valuation gap that hinges on future growth and margins holding up despite recent guidance cuts and recall headlines.

Investment in proprietary, high margin technologies (for example, next generation mapping, advanced diagnostic tools, differentiated urology and neuromodulation pipelines) combined with successful integration of recent acquisitions (Axonics, SoniVie, Intera, Silk Road) expands Boston Scientific's addressable market and is likely to drive margin expansion as product mix improves. Enhanced scale and operational efficiency through supply chain initiatives, digitalization, and manufacturing automation alongside robust cash flow positions Boston Scientific to expand operating margins and generate sustainable earnings growth over the long term.

Want to know what has to go right for that higher fair value to hold? The narrative leans on compounding revenue, firmer margins, and a richer earnings multiple than today. Curious which specific growth rates and profitability targets sit underneath those assumptions? The full narrative lays out the numbers behind that view of Boston Scientific’s potential.

Result: Fair Value of $72.25 (UNDERVALUED)

However, Boston Scientific’s story can change quickly if Watchman and electrophysiology stay weaker for longer, or if device recalls and regulatory scrutiny escalate further.

Next Steps

Overall sentiment in the Boston Scientific discussion is cautiously optimistic, and the key question is whether those potential rewards justify today’s risks. If you want to move quickly from headline reactions to your own evidence based view, start by weighing the 4 key rewards

Looking for more investment ideas beyond Boston Scientific?

If you stop with Boston Scientific, you risk missing other setups that might fit your style even better. Give yourself options and keep your opportunity set broad.

• Target potential mispricings by scanning companies that meet tight quality and value filters using the 55 high quality undervalued stocks
• Strengthen your core holdings by focusing on businesses with robust finances through the solid balance sheet and fundamentals stocks screener (45 results)
• Spot opportunities that are not yet crowded by bigger funds by checking the screener containing 19 high quality undiscovered gems

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.